Markets shrug as AbbVie's veliparib fails in two pivotal studies

20 April 2017

USA-based AbbVie (NYSE: ABBV), has announced results from two Phase III studies evaluating veliparib as a dual therapy in lung cancer and breast cancer, which show the primary endpoints were not met.

As may have been expected, given that the drug accounts for less than 1% of the company’s mid-term forecasts, investors appear unfazed by the news.

Healthcare analysts at Leerink lowered the target price for AbbVie stock by a dollar to $71, as the company’s share price held steady on the New York Stock Exchange.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK